Anju Chatterji

Dr. Anju Chatterji is the Chief Technology Officer at HilleVax. Anju has more than 20 years of experience implementing effective CMC development and manufacturing strategies to drive successful global regulatory filings and approval across multiple therapeutic areas, modalities, and phases of drug development.

Prior to joining HilleVax, Anju served as SVP of Biologics Development and Manufacturing at Catalyst Biosciences where she spearheaded strategic direction and execution of CMC Development and External Manufacturing activities, overseeing the process and analytical development as well as Manufacturing of clinical assets. At Catalyst, Anju played a key role in advancing multiple programs into the clinic, including Phase 3. Prior to this position, Dr. Chatterji served as VP of Biologics Manufacturing at Exelixis leading Biologics Development and Manufacturing. Before joining Catalyst, Anju served as Director of Technical Development at Grifols leading and defining Research and Development programs to strengthen the product pipeline. Prior to Grifols, Anju held various leadership positions of increasing responsibility at Novartis Vaccines and Diagnostics and at Bayer HealthCare growing her career in Process Sciences, MSAT, Manufacturing, and Global Biological Development functions.